B EPRIDIL, a calcium antagonist, has been used extensively in Europe as an antianginal agent.lm3 It differs from the calcium antagonists currently available in the United States (diltiazem, verapamil, and nifedipine) in several ways.4 The half-life of orally administered bepridil is 33 + 15 hours, which is considerably longer than the half-lives of currently available calcium antagonists.'g6 Bepridil is also known to act at the sodium channel, and possibly the potassium channel, producing quinidine-like effects on the cardiac action potential.7 In electrophysiologic experiments, bepridil possesses both slow calcium and fast sodium channel inhibitory activities, while other electrophysiologic studies suggest that it may possess class III antidysrhythmic properties.* Bepridil is also reported to prevent reperfusion-induced tachyarrhythmias and ventricular fibrillation in the unanesthetized dog.' It has been suggested that the volatile anesthetics, because of their intrinsic calcium channel-blocking effects, could interact with bepridil resulting in significant cardiovascular side-effects."-" Verapamil and diltiazem have potent interactions with enflurane that have not been demonstrated with halothane or isoflurane.13,14 Severe sinus node depression and advanced AV nodal block occur when verapamil is administered to animals anesthetized with enflurane, but not in animals anesthetized with halothane or isoflurane.14 The cardiac electrophysiologic interactions between the volatile anesthetics and two intravenously (IV) administered doses of bepridil were examined in this experiment. Dogs anesthetized with chloralose and given the same doses of bepridil served as controls for this experiment. Because bepridil also possesses class I antidysrhythmic properties, the effects of these interactions on atria1 and ventricular refractory periods were examined, as well as their effects on sinus and atrioventricular node function. Forty-nine mongrel dogs weighing 8 to 15 kg were divided into eight groups. Animals in groups 1 (n = 6) and 2 (n = 6) were given 10 mg of diazepam to prevent seizures, induced with 120 mg/kg of IV chloralose, and maintained BEPNIDIL INTERACTIONS   WITH VOLATILE  AGENTS  347 with 50 mg/kg/h of IV chloralose for the entire experiment. Although lower doses of chloralose have been used in the past. it was found that the dose used was necessary to ensure hemodynamic stability of the model (ie, stable pulse rate and blood pressure). Since chloralose has been shown to be an anesthetic with minimal effects on cardiac electrophysiologic parameters, these animals served as control groups for the experiment. Is Animals in groups 3 (n = 6) and 4 (n = 6) underwent inhalation induction with halothane and were maintained at 1.3% halothane end-tidal concentration (MAC = 0.87%) throughout the experiment. Animals in grW.ps 5 (n -6) and 6 (n = 7) underwent inhalation induction with enflurane and were maintained at 3.3% enflurane (MAC -2.2%) end-tidal concentration throughout the experiment. Animals in groups 7 (n = 6) and 8 (n = 6) underwent inhalation induction with isoflurane and were mazntained at 2.2% isoflurane (MAC = 1.48%) end-tidal concentration throughout the experiment. End-tidal anesthetic concentrations were monitored using a Perkin-Elmer Model 1100 medical gas analyzer. After induction, femoral arterial and venous catheters were inserted. Hydration was maintained during the experiment by infusion of 1,500 to 2,500 mL of lactated Ringer's solurion. The rate of infusion was adjusted to maintain a constant blood pressure in each dog prior to bepridil infusion. A quadripolar electrode catheter (interelectrode distance 10 mrr) was inserted via the right external jugular vein and positioned with the proximal electrode pair in the high right atrium to allow atrial pacing while the distal pair recorded the atrial electrogram. A bipolar catheter was inserted via the left internal carotid artery and advanced into the root of the aorta until optimum His-bundle recordings were obtained. The heart was exposed through a right thoraeotomy in the fifth intercostal space. A bipolar plaque electrode was sutured to the mid-right atrium approximately 1.5 cm f:om the sinoatrial (SA) node toward the right atrial appendage. Another bipolar plaque electrode was sutured to the rrght ventricle near its junction with the right atrium, thus ahowing the delivery of a second pacing stimulus (S,) to either the atrium or the ventricle during atria1 pacing via the tran*venous atrial electrode. Plaque electrodes were used to ehminate artifactual differences in the measured electrophysiologic parameters that might result from slight changes in the position of the transvenous electrode. Determinationr of sinoatrial conduction time @ACT) and corrected sinus node recovery time (CSNRT) were made during pacing wa the proximal pair of electrodes of the transvenous right atria] electrode. The atria1 electrogram, ECG, and His-butrdle electrogram were continuously displayed using a Tektronix oscilloscope while intermittent recordings of these paraneters along with blood pressure were made at designated intervals using a Gould ES-1000 recorder with filter settings of 40-300 Hz (Fig 1) . Measurements of the various inter:als were made from these recordings. High right atrial pat,ing and the delivery of atria1 and ventricular S2 stimuli were achieved using a Grass S.88 stimulator with the current measured and maintained at three times threshold, as determined at the beginning of each measurement. Esophageal temperature was measured and maintained at 36 to 38°C using a Yellow Springs Model 73A temperature controller. Arterial blood gases, serum potassium, sodium, calcium, and pH were measured periodically and maintained within the physiologic range.
After completion of the surgical preparation, baseline measurements of the following parameters were recorded: Sinus heart rate, SACT and CSNRT, atrial-His (AH) and His-ventricular (HV) intervals at pacing rates of 150, 180, and 200 beats/min (bpm), Wenckebach periodicity, and atrial and ventricular effective refractory periods at atria1 pacing rates of 120 bpm. Sinoatrial conduction time was measured as described by Narula et aLI High right atria1 pacing was performed at 5% to 10% above the sinus heart rate for eight to ten paced beats and then halted. Sinoatrial conduction time was 50% of the difference obtained when the prepacing P-P interval was subtracted from the interval between the last paced atrial beat and the first sinus escape beat on the atrial electrogram. Corrected sinus node recovery time was determined by pacing with the high right atria1 electrode for 30 seconds at heart rates of 150, 180, and 200 bpm with a one-minute rest period before each pacing interval. The first escape beat after the cessation of pacing determined the sinus node recovery time, which was defined as the interval from the last paced atria1 depolarization to the first sinus escape beat measured on the atria1 electrogram. The corrected sinus node recovery time was taken as the sinus node recovery time interval minus the immediate prepacing P-P interval at each pacing rate (150, 180, 200 bpm) . The highest of these values was recorded as the CSNRT. The AH bundle interval and the HV interval were determined at paper speeds of 250 mm/s at the rates noted. Wenckebach periodicity was obtained by increasing the atria1 pacing rate from slightly greater than spontaneous heart rate by 15 to 20 bpm after even ten paced beats until Wenckebach periodicity was observed and recorded.
Atria1 and ventricular effective refractory periods were determined by pacing with the high right atria1 electrode at a rate of 120 bpm and inserting an extra atrial or ventricular stimulus of three times diastolic threshold via the plaque electrodes. These extra stimuli were introduced into atrial or ventricular diastole with increasing prematurity in lo-ms increments each eight to ten atrially paced beats until the atrium or ventricle was refractory. The longest atrially paced P-S2 or V-S;? intervals without atria1 or ventricular capture and the shortest P-S or V-S* intervals with atrial or ventricular capture were recorded, and the refractory periods taken as the mean of these two values. The above measurements obtained in each anesthetized dog prior to the administration of bepridil served as the baseline measurements for each individual dog. Following the completion of these baseline measurements, bepridil, dissolved in 40 mL of 5% ethanol, was administered IV over 40 minutes using a Sage Model 350 infusion pump. Although faster infusion rates have been used by others, r' it was found to be difficult to maintain acceptable blood pressures when these faster infusion rates were used. Groups 1, 3, 5, and 7 received 2.5 mg/kg, while groups 2, 4, 6, and 8 received 5.0 mg/kg of bepridil. Four additional animals anesthetized with enflurane, halothane, isoflurane, and chloralose, respectively, were given 40 mL of 5% ethanol alone. The electrophysiologic measurements noted above were then repeated at 5, 15, 30, 45, and 60 minutes following the conclusion of the bepridil infusion.
Heparinized 5 mL arterial blood samples were obtained at the times noted above and stored in ice until the conclusion of the experiment. Following each experiment the plasma was separated from each sample using a Backman J6B refrigerated centrifuge. The frozen samples were shipped to the Department of Drug Metabolism of McNeil Pharmaceutical Company, Spring House, PA, where bepridil levels were determined by high-performance liquid chromatography (HPLC) assay.18
The effects of bepridil were examined in the presence of the four anesthetics using paired Student t tests with the Bonferroni correction. Differences among anesthetics were analyzed using profile analysis and analysis of variance with Scheffe corrections for multiple comparisons. When group variances were unequal, the nonparametric Kruskal-Wallis and median tests were performed.19
RESULTS
In animals anesthetized with enflurane, heart rate decreased from a baseline rate of 100 +-8 bpm to 82 + 6 bpm at the five-minute observation following 2.5 mg/kg of bepridil. Heart rate was less than 87 bpm during the remainder of the observation period in these animals. In animals anesthetized with halothane, heart rate decreased from a baseline value of 108 + 10 bpm to a rate of 88 + 8 bpm at the five-minute measurement following 2.5 mg/kg of bepridil. Heart rate continued to be depressed at rates less than 93 bpm throughout the observation period. In animals anesthetized with isoflurane, heart rate decreased from a baseline value of 103 f 3 bpm to a rate of 95 k 5 bpm at the five-minute measurement following 2.5 mg/kg of bepridil. Heart rate returned to levels measured prior to bepridil administration at the 15-minute measurement and remained at this rate during the remainder of the observation period. All values stated are significant decreases (P < .05). In animals anesthetized with chloralose, the decrease in heart rate reached significance only at the five-minute measurement. Heart rate was decreased in all groups of animals throughout the observation periods following 5 mg/kg of bepridil. There were no differences in the magnitude of change in heart rate among groups of animals anesthetized with enflurane, halothane, isoflurane, or chloralose (Fig 2) Sinoatrial conduction time was unchanged rane (4,640 to 2,460 ms + SD) compared to rhe during the observation period in all groups folgroup anesthetized with chloralose (160 to 90 lowing administration of either the 2.5 or ms * SD) (P < .Ol), while values for the halo-5-mg/kg dose of bepridil. There was, however, thane and isoflurane groups were not increased wide variability in the SACT following the ( Table 2) . administration of 5 mg/kg of bepridil in the Atrial-His intervals were unchanged rolgroup of animals anesthetized with enflurane lowing the administration of bepridil, 2.5 mg/kg, ( Table 1) . Animals anesthetized with chloralose, during any of the anesthetics evaluated. This halothane, or isoflurane demonstrated no proloninterval was prolonged following bepridil, 5 mg/ gation of CSNRT at either the 2.5-mg/kg or the kg, in animals receiving all anesthetics (Fig 3) . 5-mg/kg dose of bepridil. Mean values of Baseline AH intervals were not different when CSNRT exceeded one second at all observation anesthetic groups were compared. Animals anestimes in animals anesthetized with enflurane thetized with enflurane and receiving 5 mgJkg of receiving 5 mg/kg of bepridil. These values were bepridil demonstrated prolongation of the AH increased in the group anesthetized with enfluinterval throughout the 60-minute observation Animals anesthetized with enflurane and receiving 2.5 mg/kg of bepridil demonstrated an increase in the Wenckebach R-R interval through 45 minutes of observation when compared to baseline measurements. This parameter also increased in animals anesthetized with halothane, isoflurane, and chloralose. Animals anesthetized with enflurane and receiving 5 mg/kg of bepridil had prolongation of the Wenckebach R-R interval throughout the 60-minute observation period ( that observed in animals anesthetized with chloralose, halothane, or isoflurane following administration of bepridil, 5 mg/kg, (P -C .Ol) (Fig 4) . Values obtained prior to bepridil administration were not different when anesthetic groups were compared (chloralose 250 f 30 ms, halothane 290 + 40 ms, isoflurane 260 + 30 ms, enflurane 280 f 40 ms). Atria1 effective refractory period was increased in all animals following administration of 5 mg/kg of bepridil (Table 3 ). The increase observed in the group of animals anesthetized with enflurane was greater than those observed in the groups of animals anesthetized with chloralose, halothane, or isoflurane. Ventricular effective refractory period was unchanged in all groups following 2.5 mg/'kg of bepridil, while this measurement was proloaged in all groups following 5 mg/kg of bepridil. There were no group differences in bepriciil's effects on ventricular effective refractory period (Table 4) . Plasma concentrations of bepridil in the groups were not different following either dose during anesthesia with any of the anesthetics tested (Tables 5 and 6 ). Bepridil concentrations fell rapidly immediately after infusion of both doses of bepridil. The decline in plasma concentrations became slower thereafter. This drop in plasma bepridil levels is not inconsistent with the drug's long half-life, for it is unlikely that the linear portion of the elimination curve was reached during the course of the experiment.
for this class of drugs.',* Its apparent ability to prevent reperfusion tachydysrhythmias and ventricular fibrillation' make it an even more attractive drug to the research scientist and perhaps ultimately to the practicing physician. Importantly, bepridil serum levels persist in patients for increased periods following its discontinuance because of its prolonged half-life. Therefore, the potential for interactions with volatile anesthetic agents also persists despite discontinuance of the drug.
Intravenous administration of 40 mL of 5% ethanol, the solvent in which bepridil is dissolved, had no effect on any measurement at any time during the 60-minute observation period.
DISCUSSION
The cardiac electrophysiologic interactions between the volatile anesthetics and various calcium antagonists have been previously investigated. Significant abnormalities in both SA and AV nodal functions have been reported in dogs anesthetized with the volatile anesthetics and given verapamil.*'**' During isoflurane anesthesia, dogs receiving diltiazem have demonstrated sinus node arrest with junctional escape rhythms,22.23 while in one series second-degree heart block was also demonstrated.
Sassine et al," investigating the cardiac electrophysiologic effects of IV-administered bepridil in dogs anesthetized with pentobarbital, reported a decrease in sinus heart rate, a prolongation of sinoatrial node recovery time, an increase in atria1 refractory period, a slowing of AV nodal conduction and an increase in AV nodal refractoriness, and a lengthening of Wenckebach periodicity. Singh et a1,4 studying the cardiac electrophysiologic effects of IVadministered bepridil in unanesthetized humans, reported a decrease in sinus heart rate, an increase in the AH bundle interval, and an increase in the refractory period of the atrialventricular node with a lengthening of the Wenckebach periodicity. These studies have demonstrated the electrophysiologic effects of bepridil alone and in combination with barbiturates. Interactions of bepridil with volatile anesthetics have not been addressed.4*17 Bepridil is a unique addition to the group of In this study, sinus node function was calcium antagonists. Its long half-life, as well as assessed by three measurements: spontaneous its fast sodium channel blocking and antidysheart rate, CSNRT, and SACT. Changes in rhythmic properties, may expand the indications spontaneous heart rate reflect a combination of the direct and indirect autonomic effects of bepridil. Bepridil decreased heart rate in all groups during the observation period. These results are consistent with those obtained in animals anesthetized with pentobarbital and w&h data obtained in clinical trials.4*'9 Corrected sinus node recovery time, once thought to be strictly a reflection of sinus node automaticity, is now the most widely used measurement of sinus node function.24 The mechanism of prolongation of the CSNRT is of uncertail1 etiology, although an abnormally prolonged CSYRT does occur secondary to sinoatrial exit blcxk.25 SACT was measured to elucidate the mechanism for the prolongation of CSNRT. All animals had CSNRT of less than 500 ms at the control measurement. Sinoatrial conduction time did not increase following either 2.5 or 5 mg/kg of bepridil in animals anesthetized with chloralose, halothane, or isoflurane. In contrast, markedly prolonged CSNRT of greater than three seconds occurred in four of seven animals rec;eiving 5 mg/kg of bepridil during enflurane anesthesia. Two of the four animals in the enflurane group had prolonged SACT following the administration of 5.0 mg/kg of bepridil, while the other two animals did not. This suggests that sinoatrial conduction is important in explaining some, but not all, of the long sinus pauses following rapid atria1 pacing. It is likely that the delay in CSNRT in the two animals with abnormal SACT was due to delay in the conduction of impulses out of the sinus node, ie, sinoatrial exit block. The other two animals in the enflurane and 5.0 mg/kg of bepridil group had prolonged CSXRT while demonstrating no abnormality in sinoatrial conduction, suggesting that depression of sinus node automaticity was the probable cause of prolongation of CSNRT in these two animals.
The effect of bepridil on atrioventricular nodal function was determined by assessment of the AH interval (at 150 bpm) and the Wencke- bath R-R interval. The atria1 His-bundle in:erval at 150 bpm is a measure of the conduct ion time through the AV node at this rate. 't'he Wenckebach R-R interval correlates with the atrioventricular node effective refractory pcriod.26 At the 2.5 mg/kg dose, the depressLInt effects of bepridil on A-V nodal function were similar in all anesthetized animals. Druginduced increases in refractoriness were ;;vidented by the occurrence of Wenckebach phenomenon at slower heart rates. Atriai-t-Iis intervals at a rate of 150 bpm were largely unaffected in any anesthetic group at this &SC.: of bepridil. When bepridil, 5 mg/kg, was admiilistered, there were significant increases in cortduction times and refractoriness of the A-V node-in all anesthetic groups. The bepridil-indu::ed increases were larger, however, in the anrmals anesthetized with enflurane. Although the A-V nodal depressant effects of bepridil were greuter during enflurane anesthesia than during cbloralose, halothane, or isoflurane anesthesia, these effects were more uniform than the depressant effects on the parameters of S-A node fun&ton, The potentially catastrophic depression oi' the S-A node was not noted in the depressant efft:cts on the A-V node. No animal evidenced qpontaneous second-or third-degree heart block. The atria1 effective refractory period was increased in animals receiving 5 mgikg of bepridil and anesthetized with enflurane wiien compared to animals anesthetized with chloralose, halothane, or isoflurane. Bepridil, 5 mgjkg, produced prolongation of the ventricular zffective refractory period for 45 minutes of' ihe observation period in animals anesthetized with chloralose and halothane, and for 60 minutes in animals anesthetized with enflurane and isoBurane. These results are consistent with those of Sassine et al, who demonstrated a greater profongation of the atria1 effective refractory period than of the ventricular effective refractor!. period in animals anesthetized with pentobarbita 1 :i nd receiving 5 mg/kg of bepridil." In that study, bepridil prolonged atria1 refractory period with a minimal effect on the duration of the atria1 monophasic action potential."
Serum bepridil levels at all measurement time periods and both dosages were comparable to those reported in both human volunteers and in patients treated with bepridil for angina in doses ranging from 200 mg to 600 mg orally (PO), daily.5 Although Sassine et al" did not report serum levels in their canine study, the IV bepridil doses used in this study are comparable to those used in their study. Their results in pentobarbital-anesthetized dogs are comparable to the present chloralose-anesthetized animals."
At the 5-mg/kg dose of bepridil, depression of sinus and atrioventricular nodal conduction and of atria1 refractoriness were of greater magnitude and duration in animals anesthetized with enflurane than in animals anesthetized with chloralose, halothane, or isoflurane. This suggests that in the presence of enflurane bepridil inhibits slow calcium fluxes to a greater extent than in animals anesthetized with chloralose, halothane, or isoflurane. Consistent with this observation is the finding that the atria1 effective refractory period is increased in animals receiving enflurane, suggesting that the inhibition of the calcium fluxes could be secondary to a delayed reactivation of the calcium channel." present in this experiment following rapid atria1 pacing. In addition, one enflurane-anesthetized animal demonstrated a SACT greater than 3.5 seconds (ie, a pause following pacing at a rate just greater than spontaneous heart rate), suggesting the existence of a potential for a severe bradyarrhythmia following the use of enflurane in patients taking bepridil in the absence of a history of supraventricular tachycardia. This suggests that caution should be used in the use of enflurane in patients receiving bepridil. Depressant effects on the atrioventricular node could not be demonstrated at the 2.5-mg/kg dose of bepridil (ie, no therapeutic effects were evident at this dose in dogs). A-V nodal depression was noted at the 5-mg/kg dose, which strongly suggests that this is an appropriate dose for study of this drug in dogs.
The combination of bepridil, 5.0 mg/kg, and enflurane, 3.3% (MAC = 2.2%), caused severe sinus node dysfunction as measured by CSNRT. Since one of the potential clinical uses of bepridil is the treatment of supraventricular tachycardia, patients with a history of paroxysmal supraventricular tachycardia may be scheduled for surgery while receiving bepridil. The combination of enflurane and an episode of supraventricular tachycardia in these patients could result in conditions analogous to those In summary, these data clearly demonstrate that the calcium-blocking actions of bepridil are more pronounced during enflurane anesthesia than during chloralose, halothane, or isoflurane anesthesia in dogs. Following the IV administration of 5 mg/kg of bepridil, severe sinus node dysfunction occurred in half of the animals anesthetized with enflurane. This was demonstrated both by prolonged CSNRT and by prolonged SACT. In at least two cases, the abnormal sinus node function was presumably due to sinoatrial node exit block. Atrioventricular nodal function is depressed more by bepridil in animals anesthetized with enflurane than in animals anesthetized with halothane, isoflurane, or chloralose. No spontaneous second-or thirddegree heart block was demonstrated, however, following either dose of bepridil with any of the anesthetic agents. In addition, if the pacing function of the sinus node is inhibited, other pacemakers in the atrioventricular junction cannot be relied upon to maintain heart rate since they are depressed by inhalational anesthetics.27
